Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.59 |
| ▸ | TNNI3K | Q59H18 | 9/20 | 0.59 |
| ▸ | RAF1 | P04049 | 5/20 | 0.54 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776544 | 0.85 | KDR (0.50) | KDRTNNI3KRAF1MAP2K7MAPK14 | |
| SCHEMBL22592313 | 0.80 | KDR (0.67) | KDRTNNI3KRAF1MAP2K7MAPK14 | |
| SCHEMBL2778530 | 0.79 | KDR (0.47) | KDRTNNI3KRAF1MAP2K7MAPK14 | |
| SCHEMBL2434197 | 0.79 | KDR (0.70) | KDRTNNI3KRAF1MAP2K7MAPK14 | |
| SCHEMBL3177337 | 0.78 | KDR (0.58) | KDRTNNI3KRAF1MAP2K7MAPK14 | |
| SCHEMBL4548796 | 0.76 | KDR (0.84) | KDRTNNI3K | |
| SCHEMBL7790214 | 0.76 | HAO1 (0.47) | KDR | |
| SCHEMBL4822084 | 0.73 | KDR (0.54) | KDRTNNI3KMAPK14BRAF | |
| SCHEMBL15135487 | 0.73 | KDR (0.50) | KDRMAP2K7 | |
| SCHEMBL2709280 | 0.73 | KDR (0.56) | KDRTNNI3KRAF1MAP2K7MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885TNNI3K 1828/4885RAF1 524/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885TNNI3K 1828/4885RAF1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.